


Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of the Claims

1. (currently amended): A compound ~~comprising~~ of Formula (I), or a pharmaceutically acceptable salt thereof:



wherein

A is a zinc ligand or zinc ligand bearing moiety selected from the group consisting of:



B is $\begin{array}{c} \text{R}_{11} \\ | \\ \text{---N---CH}_2\text{---} \end{array}$ or absent :

R is hydrogen or lower alkyl;

R₁ is hydrogen or lower alkyl;

R₂ is hydrogen, or lower alkyl;

R₃ is hydrogen or lower alkyl;


R₄ is lower alkyl, substituted lower alkyl, cycloalkyl-(CH₂)_w-, aryl-(CH₂)_w-, substituted aryl-(CH₂)_w- or heteroaryl-(CH₂)_w-;

R₅ is hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl-(CH₂)_x-, aryl-(CH₂)_x-, substituted aryl-(CH₂)_x-, or heteroaryl-(CH₂)_x-;

~~R₆ is hydrogen, R₇-CO-, or R₁₂-S-~~

~~R₇ is alkyl, substituted alkyl, cycloalkyl-(CH₂)_y-, aryl-(CH₂)_y-, substituted aryl-(CH₂)_y- or heteroaryl-(CH₂)_y-;~~


R₈ and R₉ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl-(CH₂)_y-, substituted aryl-(CH₂)_y-, heteroaryl-(CH₂)_y-,



R₁₀ is alkyl, substituted alkyl, cycloalkyl-(CH₂)_y-, aryl-(CH₂)_y-, substituted aryl-(CH₂)_y- or heteroaryl-(CH₂)_y-;

~~R₁₁ is hydrogen or lower alkyl;~~

~~R₁₂ is alkyl, substituted alkyl, cycloalkyl-(CH₂)_y-, aryl-(CH₂)_y-, substituted aryl-(CH₂)_y- or heteroaryl-(CH₂)_y-;~~



~~in which case S R₁₂ completes a symmetrical disulfide;~~

R₁₃ is hydrogen, lower alkyl, cycloalkyl or phenyl;


R₁₄ is hydrogen, lower alkyl, lower alkoxy or phenyl;

R₁₅ is lower alkyl or aryl-(CH₂)_y-;

D is ~~-COOH, -SO₂H, -SO₃H, -PO₃H₂, -OSO₃H or -OPO₃H₂;~~

E is hydrogen, R₁₂, -COOH, -CONH₂, -CONH(lower alkyl), -CON(lower alkyl)₂,
-CONH-(CH₂)_z-aryl, -CON(-(CH₂)_z-aryl)₂, -CO-amino acid, -CH₂COOH,
CH₂OH, -CH₂CH₂OH, or -COOR₁₆;

R₁₆ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl-
(CH₂)_y-, substituted aryl-(CH₂)_y-, heteroaryl-(CH₂)_y-;



C is carbon;

H is hydrogen;

O is oxygen;

N is nitrogen;

S is sulfur;

P is phosphorus;

v is zero or one;

w is zero or an integer ranging from 1 to 4;

x is an integer ranging from 1 to 4;

y is zero or an integer ranging from 1 to 6; and

z is zero, one, two, or three.

Claims 2-6 (canceled).

7. (original): The compound of claim 1, wherein R₁ and R₃, when v=0, are connected together to form an alkylene bridge of 3 carbon atoms representing with the carbon atoms to which they are attached a cyclopentane ring.

8. (original): The compound of claim 1, wherein R₁ and R₃, when v=0, are connected together to form an alkylene bridge of 4 carbon atoms representing with the carbon atoms to which they are attached a cyclohexane ring.
9. (canceled).
10. (original): The compound of claim 1, wherein R and R₄ are connected together to form an alkylene bridge of 3 carbon atoms representing with the nitrogen and carbon atoms to which they are attached a pyrrolidine ring.
11. (original): The compound of claim 1, wherein R and R₄ are connected together to form an alkylene bridge of 4 carbon atoms representing with the nitrogen and carbon atoms to which they are attached a piperidine ring.

Claims 12-15 (canceled).

16. (currently amended): The compound of claim 1, wherein the compound is further defined as: ~~N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-acetyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-phenyl-propionyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-propionyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-4-methyl-pentanoyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-3-methyl-butyryl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-hydroxy-2-mercapto-propionyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-hydroxy-2-mercapto-butyryl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-hexanoyl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-4-phenyl-butyryl-amino)-succinamic-acid[[,]]₁; N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-2-phenyl-acetyl-amino)-succinamic-acid[[,]]₁; 3-(3-Biphenyl-4-yl-2-mercapto-propionyl-amino)-N [1-Carboxy-2-(1H-indol-3-yl)-ethyl]-succinamic~~


~~acid[[,]]_i 3 (3 (4 Benzyloxy phenyl) 2-mercapto-propionylamino) N [1-Carboxy 2 (1H-indol 3-yl) ethyl] succinamic acid[[,]]_i N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 [3 (4-fluoro phenyl) 2-mercapto-propionylamino] succinamic acid[[,]]_i N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 [2-mercapto-3 (4-methoxy phenyl) propionylamino] succinamic acid[[,]]_i N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 (3-cyclohexyl 2-mercapto-propionylamino) succinamic acid[[,]]_i N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 [3 (1H-indol 3-yl) 2-mercapto-propionylamino] succinamic acid[[,]]_i N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 (2-mercapto-3-naphthalen-2-yl propionylamino) succinamic acid[[,]]_i N (1-Carboxy 2-naphthalen-2-yl ethyl) 3 (2-mercapto-3-phenyl propionylamino) succinamic acid[[,]]_i N (1-Carboxy 2-hydroxy ethyl) 3 (2-mercapto-3-phenyl propionyl amino) succinamic acid[[,]]_i N [1-Carboxy 2 (4-hydroxy phenyl) ethyl] 3 (2-mercapto-3-phenyl propionylamino) succinamic acid[[,]]_i N [1-Carboxy 2-phenyl ethyl] 3 (2-mercapto-3-phenyl propionyl amino) succinamic acid[[,]]_i N (2-Biphenyl 4-yl 1-Carboxy ethyl) 3 (2-mercapto-3-phenyl propionyl amino) succinamic acid[[,]]_i N (1-Benzyl 2-hydroxy ethyl) 3 (2-mercapto-3-phenyl propionyl amino) succinamic acid, N [1-Carboxy 2 (1H-indol 3-yl) ethyl] 3 (2-mercapto-3-phenyl propionylamino) succinamic acid[[,]]_i 4 [1-Carboxy 2 (1H-indol 3-yl) ethylcarbamoyl] 4 (2-mercapto-3-phenyl propionylamino) ethyl] butyric acid[[,]]_i N [2 (1H-indol 3-yl) methylcarbamoyl ethyl] 3 (2-mercapto-acetyl amino) succinamic acid[[,]]_i N [1 (1-Carboxy 2-hydroxy ethylcarbamoyl) 2 (1H-indol 3-yl) ethyl] 3 (2-mercapto-3-phenyl propionylamino) succinamic acid[[,]]_i N [2 (1H-indol 3-yl) methoxycarbonyl ethyl] 3 (2-mercapto-acetyl amino) succinamic acid[[,]]_i N [2 (1H-indol 3-yl) ethyl] 3 (2-mercapto-3-phenyl propionylamino) succinamic acid[[,]]_i 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid[[,]]_i 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]_i 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid[[,]]_i 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid[[,]]_i 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid[[,]]_i 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]_i 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid[[,]]_i 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid[[,]]_i 4-Hydroxycarbamoyl-3-(5-~~

hydroxy-pentylcarbamoyl)-butyric acid[,,]; 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid[,,]; ~~3-(2-Biphenyl-4-yl-ethylcarbamoyl)-5-hydroxycarbamoyl-pentanoic acid[,,];~~ N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid[,,]; or 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.


17. (currently amended): The compound of claim 16, wherein the compound is ~~further defined as~~ 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.
18. (original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a physiologically acceptable carrier or excipient.
19. (currently amended): The pharmaceutical composition of claim 18, wherein the compound ~~of claim 1~~ is further defined as: ~~a compound of claim 16~~ 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid; 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid; 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid; 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid; 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid; 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid; 4-Hydroxycarbamoyl-3-(5-hydroxy-pentylcarbamoyl)-butyric acid; 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid; N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid; or 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.
20. (currently amended): The pharmaceutical composition of claim 18, wherein the compound ~~of claim 1~~ is further defined as the compound of claim 17 as 3-(2-Biphenyl-4-yl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.

Claims 21-33 (canceled).


34. (new): The compound of claim 1, wherein A is




35. (new): The compound of claim 1, wherein A is




36. (new): The compound of claim 1, wherein A is



37. (new): The compound of claim 1, wherein A is



38. (new): The compound of claim 1 having the formula:



39. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Cyano-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.
40. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-[2-(4-pyridin-2-yl-phenyl)-ethylcarbamoyl]-butyric acid.
41. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(4-phenyl-butylcarbamoyl)-butyric acid.
42. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(2-phenoxy-ethylcarbamoyl)-butyric acid.
43. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Hydroxy-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.
44. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-(2,2-Diphenyl-ethylcarbamoyl)-4-hydroxycarbamoyl-butyric acid.
45. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[2-(4'-Dimethylamino-biphenyl-4-yl)-ethylcarbamoyl]-4-hydroxycarbamoyl-butyric acid.

46. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 4-Hydroxycarbamoyl-3-(5-hydroxy-pentylcarbamoyl)-butyric acid.
47. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-[(Biphenyl-4-ylmethyl)-carbamoyl]-4-hydroxycarbamoyl-butyric acid.
48. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as N-[1-carboxy-2-(1H-indol-3-yl)-ethyl]-3-(3-phenyl-1-phosphono-propylamino)-succinic acid.
49. (new): The pharmaceutical composition of claim 19, wherein the compound is further defined as 3-(2-Naphthalen-2-yl-ethylcarbamoyl)-pentanedioic acid.